Business Practice
CME/CE
Subscribe
BIOSIMILAR APPROVALS
Authors
Tyler Sandahl, PharmD
Latest:
Balancing Cost Savings With Clinical Practice for Multiple Myeloma Biosimilars: Tyler Sandahl, PharmDTyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, supports biosimilars for cost savings but foresees challenges adopting an intravenous daratumumab biosimilar, preferring the more convenient subcutaneous option.
University of Arizona R. Ken Coit College of Pharmacy
Latest:
Dr Ivo Abraham Column: Biosimilars and the Commoditization of TreatmentsIvo Abraham, PhD, chief scientist of Matrix45 and a professor at the University of Arizona, explores whether biosimilars should be considered a commodity and if the commodification of medications is sustainable as the market continues to expand.
